
Logistics & Transportation
Latest News
Latest Videos

Podcasts
More News

LogiPharma's Charleen Ring and McKesson's Chris Van Norman preview the 2026 agenda, sessions to prioritize and a day two fireside chat.

GLP-1 demand is straining pharma cold chain capacity, from tighter temperature thresholds and rising load rejections to fuel costs and trailer backlogs.

HDA's Kala Shankle says a federal licensure baseline could bring real efficiency gains for wholesale distributors and 3PLs, but only if state requirements align and every stakeholder moves on the same timeline.

Temperature excursions cost pharma an estimated $35 billion a year as biologics, GLP-1s and cell and gene therapies raise cold chain stakes.

Overhaul's Danny Ramon argues that quality and regulatory teams, not just logistics, need faster protocols and more accessible stability data, since stolen or compromised product that reenters the supply chain through gray markets can ultimately reach patients.

IAG Cargo has added a Kuala Lumpur station to its Constant Climate network, its 13th in Asia-Pacific, as regional biologics and personalized medicine demand accelerates.

Dual chokepoint disruptions in the Gulf and Red Sea are pushing shippers toward longer, costlier routes with no resolution in sight.

Cleveland Clinic's new prescription drone delivery program and Arrive AI's planned collaboration with LifeSpan Pharmacy highlight growing interest in drone technology for last-mile logistics.

Kenco has put DeepFabric's AI agents into live production across its 3PL operations, with plans to scale to 20 agents within a year.

Ember LifeSciences and Alfresa, Japan's top pharma wholesaler, form a cold chain alliance as biologics and specialty distribution demand grows.

Geopolitical instability is pushing life sciences firms to map supply chains beyond suppliers to protect trials and patient access.

Continuous monitoring, targeted automation and interoperability standards are redefining pharma cold chain custody and cutting temperature excursions.

EVERSANA's Danny Williams on how cell and gene therapies, AI, and direct-to-patient fulfillment are reshaping the pharma 3PL model.

As CGTs scale from clinical to commercial, Cencora's Krystal Haynes discusses the supply chain decisions that determine whether a launch succeeds.
















